AngioDynamics Inc. (ANGO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended November 30, 2024 (Q2 of Fiscal Year 2025). AngioDynamics is a medical technology company focused on vascular access, peripheral vascular disease treatment, and oncology/surgical devices. The company operates through two segments: Med Tech (Auryon, thrombus management, NanoKnife) and Med Device (vascular access, oncology, surgical). The period reflects the ongoing impact of recent divestitures (PICCs, Midlines, Dialysis, BioSentry) and a strategic restructuring plan to shift manufacturing to an outsourced model.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Sales | $72.8 million | $79.1 million | $140.3 million | $157.8 million |
| Gross Profit | $39.9 million | $40.3 million | $76.6 million | $80.3 million |
| Gross Margin | 54.8% | 50.9% | 54.6% | 50.9% |
| Operating Loss | $(11.1) million | $(13.1) million | $(24.2) million | $21.9 million |
| Net Loss | $(10.7) million | $(29.0) million | $(23.5) million | $16.8 million |
| Diluted EPS | $(0.26) | $(0.72) | $(0.58) | $0.42 |
| Cash & Equivalents | $54.1 million | (Balance Sheet data) | ||
| Operating Cash Flow | $(15.8) million (YTD) | $(20.6) million (YTD) | (6 Months Ended Nov 30) | |
| Debt | $0 | (No outstanding debt) |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 7.9% QoQ and 11.0% YTD compared to the prior year. This is primarily due to the divestiture of PICCs, Midlines, Dialysis, and BioSentry businesses, as well as the discontinuation of the RadioFrequency Ablation and Syntrax product lines.
- Segment Performance:
- Med Tech: Revenue grew 24.4% QoQ and 16.2% YTD, driven by increased sales of Auryon, the thrombus management platform (AngioVac/AlphaVac), and NanoKnife.
- Med Device: Revenue declined 23.1% QoQ and 24.1% YTD, heavily impacted by the divestitures mentioned above.
- Margin Expansion: Despite lower revenue, gross margin improved by 390 basis points QoQ (to 54.8%) and 370 basis points YTD (to 54.6%), driven by favorable product mix and cost management.
- Restructuring Costs: The company incurred $5.1 million in restructuring charges in Q2 and $8.7 million YTD related to the "Plan" to restructure its manufacturing footprint and shift to an outsourced model. Total restructuring charges to date are $18.2 million.
- Legal Settlement: A $7.0 million settlement was reached with C.R. Bard/BD regarding patent litigation, with $3.0 million paid immediately and the remainder payable in installments.
Guidance, Outlook, and Risks
- Restructuring Outlook: The modified manufacturing restructuring plan is expected to be completed in Q3 of Fiscal 2026 and is projected to generate $15.0 million in annual cost savings by Fiscal 2027.
- Liquidity: Management believes current cash ($54.1 million) and operating cash flows are sufficient to meet needs for at least the next 12 months. The company has no outstanding debt.
- Share Repurchase: A $15.0 million share repurchase program was authorized in July 2024. As of Nov 30, 2024, $13.3 million remains available. The company repurchased 171,706 shares in Q2.
- Risks:
- Legal: Approximately 50 product liability claims remain pending regarding port products. A contingent payment of $3.0 million to BD is possible if a Federal Circuit appeal reverses previous findings of patent invalidity.
- Execution: Risks associated with the transition to third-party manufacturing and the integration of the modified restructuring plan.
- Market: Exposure to foreign currency fluctuations (approx. 3.4% of sales in foreign currencies) and macroeconomic factors like inflation and supply chain constraints.
Investor Verification Checklist
- Divestiture Impact: Verify the long-term revenue trajectory of the remaining Med Device portfolio post-divestiture.
- Restructuring Execution: Monitor the timeline and cost savings realization of the manufacturing outsourcing plan (targeting Q3 FY2026 completion).
- Legal Contingencies: Track the status of the Federal Circuit appeal regarding the BD patent settlement and the outcome of the ~50 pending port product liability claims.
- Cash Burn: Assess the sustainability of the current operating cash burn ($15.8 million YTD) against the $54.1 million cash balance.
- Med Tech Growth: Confirm if the double-digit growth in the Med Tech segment (Auryon, Thrombus) can offset the structural decline in Med Device sales.